Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: A retrospective study in a single institute in Japan

Japanese Journal of Clinical Oncology

Volumn 45, Issue 1, 2015, Pages 61-66

  Inoue, Dai ^a   Ozaka, Masato ^a   Matsuyama, Masato ^a   Yamada, Ikuhiro ^a   Takano, Koichi ^a   Saiura, Akio ^a   Ishii, Hiroshi ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

CRP; MGPS; NLR; PLR; Survival

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLASGOW PROGNOSTIC SCALE; HISTOLOGY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; NEUROENDOCRINE TUMOR; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PLATELET LYMPHOCYTE RATIO; RETROSPECTIVE STUDY; SURVIVAL TIME; BLOOD; LYMPHOCYTE; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; NEUTROPHIL; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; JAPAN; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84922354094     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu159     Document Type: Article

References (20)

1. Vital Statistics Japan (Ministry of Health, Labour and Welfare).
2. David M, Lepage C, Jouve J-L, et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 2009;101:215-8.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
5. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-6.
6. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856-64.
7. Schmidt H, Suciu S, Punt CJ, et al. American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007;20: 1562-9.
8. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007;110:1241-7.
9. Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013;13:350.
10. Absenger G, Szkandera J, Pichler M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395-400.
11. Morrison DS, McMillan DC. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 2010;103:870-6.
12. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012;107:695-9.
13. Pine JK, Fusai KG, Young R, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2009;35:605-10.
14. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010;200:197-203.
15. Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor-and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2011;18:2318-28.
16. La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2012; 19:2917-23.
17. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014;155:977-88.
18. Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416-21.
19. Szkandera J, Stotz M, Eisner F, et al. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS ONE 2013;8:e78225.
20. Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 2014;110:183-8.